RIPK1 and amyotrophic lateral sclerosis: Activation of RIPK1 has been observed in human ALS spinal cord samples.6 In studies involving mouse models of ALS, the activation of RIPK1 kinase has been demonstrated to promote neuroinflammation and progressive degeneration of motor neurons in the pathogenesis of ALS which can be inhibited by genetic and pharmacological inactivation of RIPK1.6–8 However, human clinical studies on developing a RIPK1 inhibitor for the treatment of ALS have been less than straight-forward.